Levran O, Desnick R J, Schuchman E H
Division of Medical and Molecular Genetics, Mount Sinai School of Medicine, New York, New York 10029.
J Clin Invest. 1991 Sep;88(3):806-10. doi: 10.1172/JCI115380.
Types A and B Niemann-Pick disease both result from the deficient activity of the lysosomal hydrolase, acid sphingomyelinase (E.C. 3.1.4.12). Type A Niemann-Pick disease is a severe neurodegenerative disorder of infancy which leads to death by three years of age, whereas Type B disease has a later age at onset, little or no neurologic involvement, and most patients survive into adulthood. To investigate the molecular basis for the remarkable phenotypic heterogeneity, the nature of the mutations causing Type B Niemann-Pick disease in Ashkenazi Jewish patients was determined. The entire acid sphingomyelinase coding region from an Ashkenazi Jewish Type B patient was polymerase chain reaction-amplified, subcloned, and completely sequenced. A three-base deletion was identified of nucleotides 1821-1823 in the cDNA which predicted the removal of an arginine residue from position 608 of the acid sphingomyelinase polypeptide (delta R608). The other cDNA clones from this patient had the R496L mutation previously identified in Type A Niemann-Pick disease patients. Both Ashkenazi Jewish Type B patients were heteroallelic for the delta R608 mutation, whereas this allele was not present in 15 unrelated non-Jewish Type B patients, with the notable exception of one mildly affected patient of Arabic descent who was homoallelic for the delta R608 mutation. These results indicate that the delta R608 mutation predicts the Type B Niemann-Pick disease phenotype, even in the presence of the R496L Type A allele, thereby providing the first genotype/phenotype correlation for this lysosomal storage disease. Although only two patients have been studied, it appears that the delta R608 mutation occurs frequently in Type B Niemann-Pick disease patients of Ashkenazi Jewish descent.
A型和B型尼曼-匹克病均由溶酶体水解酶酸性鞘磷脂酶(E.C. 3.1.4.12)活性不足所致。A型尼曼-匹克病是一种严重的婴儿期神经退行性疾病,通常在三岁前死亡,而B型疾病发病较晚,很少或没有神经系统受累,大多数患者可存活至成年。为了研究这种显著表型异质性的分子基础,确定了导致阿什肯纳兹犹太患者患B型尼曼-匹克病的突变性质。对一名阿什肯纳兹犹太B型患者的整个酸性鞘磷脂酶编码区进行聚合酶链反应扩增、亚克隆并完全测序。在cDNA中鉴定出1821 - 1823位核苷酸的三碱基缺失,这预测酸性鞘磷脂酶多肽第608位的精氨酸残基将被去除(ΔR608)。该患者的其他cDNA克隆具有先前在A型尼曼-匹克病患者中鉴定出的R496L突变。两名阿什肯纳兹犹太B型患者均为ΔR608突变的杂合子,而该等位基因在15名无关的非犹太B型患者中不存在,但有一名阿拉伯裔轻度受累患者除外,该患者为ΔR608突变的纯合子。这些结果表明,即使存在R496L型A等位基因,ΔR608突变也预示着B型尼曼-匹克病的表型,从而为这种溶酶体贮积病提供了首个基因型/表型相关性。尽管仅研究了两名患者,但似乎ΔR608突变在阿什肯纳兹犹太裔B型尼曼-匹克病患者中频繁出现。